Windtree Therapeutics, Inc. Selling, General and Administrative Expense of Revenue

Selling, General and Administrative Expense of Revenue of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative Expense of Revenue for the quarter ending June 29, 2020 was 0.0% (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative Expense of Revenue decreased by NaN%
  • Annual Selling, General and Administrative Expense of Revenue for 2019 was 6264.65% (a 1409.41% increase from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2018 was 415.04% (a -7.42% decrease from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2017 was 448.28% (a 9.33% increase from previous year)
  • Twelve month Selling, General and Administrative Expense of Revenue ending June 29, 2020 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative Expense of Revenue decreased by NaN% year-over-year
Trailing Selling, General and Administrative Expense of Revenue for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
0.0% 0.0% 2470.92% 0.0%
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative Expense of Revenue of Windtree Therapeutics, Inc.

Most recent Selling, General and Administrative Expense of Revenueof WINT including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative Expense of Revenue of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Selling, General and Administrative Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0% 0.0%
2019 0.0% 0.0% 2050.63% 8387.5% 6264.65%
2018 916.78% 655.02% 114.94% 944.12% 415.04%
2017 1158.82% 10288.24% 157.28% 877.63% 448.28%
2016 146.67% 167.85% 1682.08% 4876.0% 410.04%
2015 337.56% 3116.67% 4510.67% 1755.5% 1114.89%
2014 315.63% 782.92% 406.77% 14267.74% 590.19%
2013 5500.0% 7165.0% 2268.68% 5861.11% 4308.76%
2012 0.0% 0.0% 0.0% 0.0% 8432.82%
2011 0.0% 0.0% 978.11% 477.69% 1351.2%
2010 0.0% 0.0% 0.0% 0.0% 0.0%

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.